Gadobutrol is a paramagnetic, gadolinium-based contrast agent (GBCA) indicated for use during magnetic resonance imaging (MRI) to assess myocardial perfusion in patients with known or suspected coronary artery disease, assess the presence and extent of malignant breast disease, and detect and visualize areas with disrupted blood-brain barrier and/or abnormal vascularity within the central nervous system (CNS). It is also used in magnetic resonance angiography (MRA) to evaluate known or suspected supra-aortic or renal artery disease. Gadobutrol, like all GBCAs, carries a black box warning for nephrogenic systemic fibrosis (NSF). NSF is a serious condition that may result in fatal or debilitating fibrosis of the skin, muscle, and internal organs. The propensity to cause NSF differs among available GBCAs; few, if any, confirmed cases have been associated with gadobutrol while most unconfounded cases have been reported with gadodiamide, gadopentetate dimeglumine, and gadoversetamide.
General Administration Information
For storage information, see the specific product information within the How Supplied section.
NOTE: Hypersensitivity reactions may occur. Prior to administration, assess all patients for previous reactions to contrast media. Trained personnel and therapies used to treat hypersensitivity reactions (epinephrine, antihistamines, and corticosteroids) should be readily available. Observe patient for signs and symptoms of hypersensitivity reactions during and after administration.
Route-Specific Administration
Injectable Administration
-Visually inspect for particulate matter and discoloration prior to administration. Solution is clear, colorless to pale yellow. Do not use if discolored or if particulate matter is present.
-Do not mix with other medications. Do not administer other medications in the same intravenous line.
Intravenous Administration
-Use aseptic technique when preparing and administering gadobutrol.
-Ensure catheter and venous patency before the injection. Extravasation may result in tissue irritation.
Single-dose vials
-Draw gadobutrol into the syringe immediately before use.
-Do not pierce the rubber stopper more than once.
-Storage: The product contains no antimicrobial preservatives. Discard any unused vial contents.
Prefilled syringes
-Remove tip cap immediately before use.
-Storage: The product contains no antimicrobial preservatives. Discard any unused syringe contents.
Bulk package
-The bulk package contains many single doses of gadobutrol. It is for intravenous use and not for direct infusion.
-Use the bulk package only with an automated contrast injection system, contrast management system, or contrast media transfer set approved or cleared for use with gadobutrol.
-The bulk package is to be used only in a room designated for radiological procedures that involve intravascular administration of a contrast agent.
-Penetrate the container closure only once with a suitable sterile component of the automated contrast injection system, contrast management system, or contrast transfer set (e.g., transfer spike).
-Once punctured, do not remove the bulk package from the work area during the entire period of use. If the integrity of the bulk package and the delivery system cannot be assured through direct continuous supervision, discard the bulk package and all associated disposables for the automated contrast injection system, contrast management system, or contrast media transfer set.
-Storage: After the container closure has been entered, store the bulk package between 20 to 25 degrees C (68 to 77 degrees F). A maximum use time of 24 hours from the initial puncture is permitted to complete fluid transfer. Discard any unused product 24 hours after the initial puncture.
Cardiac MRI
-Administer total dose via 2 separate, equal IV injections by power injector at a flow rate of approximately 4 mL/second. Give the first injection during peak pharmacologic stress and second injection at rest.
-Follow each injection with a 20 mL 0.9% Sodium Chloride Injection flush, at a flow rate of approximately 4 mL/second.
-If concomitantly administering a continuous infusion of a pharmacologic stress agent, administer gadobutrol through a separate IV line in the contralateral arm.
MRI of the Breast
-Administer as an intravenous bolus by power injector.
-Follow with a 0.9% Sodium Chloride Injection flush to ensure complete administration of the contrast.
-Start image acquisition after contrast administration and then repeat sequentially to determine peak intensity and wash-out.
MRI of the Central Nervous System
-Administer as an intravenous injection, manually or by power injector, at a flow rate of approximately 2 mL/second.
-Follow with a 0.9% Sodium Chloride Injection flush to ensure complete administration of the contrast.
-Post-contrast MRI can begin immediately after contrast administration.
MRA
-Image acquisition should coincide with peak arterial concentration, which varies among patients.
-Adults: Administer by power injector, at a flow rate of approximately 1.5 mL/second. Follow with a 30 mL 0.9% Sodium Chloride Injection flush at the same rate to ensure complete administration of the contrast.
-Pediatrics: Administer by power injector or manually. Follow with a 0.9% Sodium Chloride Injection flush to ensure complete administration of the contrast.
Cases of nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy) (NSF/NFD) have been reported after administration of gadolinium-based contrast agents (GBCAs) in patients with moderate to severe renal impairment. This reaction has been reported during postmarketing use of gadobutrol. In fact, an association of any 1 specific GBCA and the development of NSF/NFD is not always identified; most reports have involved the use of gadodiamide, gadopentetate dimeglumine, and gadoversetamide. In a retrospective study of 370 patients with severe renal insufficiency, the estimated risk for NSF/NFD was 4%. In a report by the CDC, a case-control study from a single hospital found that the risk of NSF/NFD is higher in patients undergoing peritoneal dialysis compared to hemodialysis (estimated 4.6 cases/100 peritoneal dialysis patients vs. 0.61 cases/100 hemodialysis patients). The mechanism of NSF/NFD in patients receiving GBCAs is unknown; however, dissociation of gadolinium from its chelating agent after intravenous injection is hypothesized. The free gadolinium ion then binds to anions such as phosphate, resulting in an insoluble precipitate that deposits in various tissues, and a fibrotic reaction ensues. NFD is characterized by burning, itching, swelling, scaling, tightening, and hardening of the skin, red or dark patches on the skin, stiffness in joints, resulting in trouble moving, straightening or bending the arms, legs or feet; muscle weakness, pain in hip bones or ribs. NSF involves fibrosis of organs (e.g., heart, liver, lungs) and can lead to death. Diagnosis of NSF/NFD is confirmed by skin biopsy. Patients at risk for NSF due to exposure to GBCAs include certain patients with renal insufficiency and those receiving repeated or higher than recommended doses. Although efficacy of hemodialysis for the prevention of NSF/NFD is unknown, healthcare providers may consider prompt initiation of a hemodialysis session after administration of GBCAs to aid in the elimination of the agent from the body for those patients already receiving hemodialysis. Hemodialysis is preferred to peritoneal dialysis as available data indicate that continuous ambulatory peritoneal dialysis may not be as efficient as hemodialysis in eliminating GBCAs. Treatment options for NSF/NFD are minimal; patients should be enrolled in physical therapy programs. Limited data in support of plasmapheresis or photopheresis are promising.
Cases of acute renal failure (unspecified), some requiring treatment with dialysis, have developed following administration of gadolinium-based contrast agents (GBCAs) to patients with pre-existing chronic renal insufficiencies. The risk for acute renal injury appears to be dose-related; therefore, use of the lowest dose necessary for adequate imaging is recommended. Monitor renal function in patients receiving GBCAs.
Hypersensitivity or anaphylactoid reactions, characterized by cardiovascular, respiratory, and cutaneous symptoms, have been associated with the use of all gadolinium-based contrast agents (GBCAs), including gadobutrol (less than 0.1%). Most cases develop within 30 minutes of drug administration; however delayed reactions, occurring up to several days after administration, have been reported. Some of the symptoms associated with these reactions may include anaphylactic shock, cardiac arrest, cyanosis, respiratory arrest, bronchospasm, pulmonary edema, angioedema, laryngeal edema, oropharyngeal swelling, hypertension, chest pain (unspecified), conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor. Rash (including generalized, pruritic, and maculopapular rash) (0.3%), pruritus (0.2%), erythema (0.2%), dyspnea (0.1%), and urticaria (0.1%) have been observed with gadobutrol in clinical trials. Monitor patients for these symptoms, both during and after drug administration.
Injection site reaction and feeling of warmth were reported in 0.4% of gadobutrol recipients during clinical trials. Other adverse events reported in less than 0.1% patients and possibly associated with the administration of the drug included malaise and feeling cold. Take precautions to avoid extravasation and potential tissue irritation, ensure catheter and venous patency prior to administering.
Headache (1.7%), dizziness (0.5%), dysgeusia (0.4%), and paresthesias (0.2%) were among the most frequently reported adverse events during clinical trials involving gadobutrol. Other neurologic adverse events reported in less than 0.1% of drug recipients include loss of consciousness, convulsions, and parosmia.
Gastrointestinal adverse events reported by patients receiving gadobutrol during clinical trials include nausea (1.2%), vomiting (0.4%), and xerostomia (less than 0.1%).
Sinus tachycardia and palpitations were observed in less than 0.1% of gadobutrol recipients during clinical trials.
Diagnostic procedures that involve use of contrast agents, such as gadobutrol, should be carried out under direction of a physician with the prerequisite training and a thorough knowledge of the procedure to be performed. As with any paramagnetic contrast agent, use of gadobutrol during contrast enhanced magnetic resonance imaging (MRI) could impair visualization of lesions seen on non-contrast MRI. Caution must be used when contrast-enhanced imaging is interpreted without a companion non-contrast image. Healthcare providers are also advised of the potential for a MRI of the breast to overestimate the degree of malignant disease present; gadobutrol-enhanced MRIs overestimated the histologically confirmed extent of malignant breast disease in up to 50% of patients. In addition, gadolinium deposits may remain in patients' bodies for months to years after gadolinium-based contrast agent (GBCA) receipt. Bone has been identified as the main reservoir, retaining the highest concentration of gadolinium (nanomoles per gram of tissue) for the longest duration of time. Other organs which retain lesser amounts of gadolinium include the brain, skin, kidney, liver, and spleen. The consequences of gadolinium retention in the brain have not been established; however, retention in the skin and kidney has been associated with pathologic clinical consequences in patients with impaired renal function. There are rare reports of pathologic skin changes in patients with normal renal function. Other patients who may be at higher risk for gadolinium retention include patients requiring multiple lifetime doses, pregnant women, pediatric patients, and patients with inflammatory conditions. Limit repeated GBCA imaging studies, particularly closely spaced MRI studies, but do not defer or avoid necessary GBCA MRI scans. When choosing a GBCA, consider the retention characteristics of each agent. In general, linear GBCAs result in more retention and retention for longer periods of time than do macrocyclic GBCAs. More specifically, at equivalent doses, use of gadodiamide or gadoversetamide results in higher gadolinium concentrations remaining in the body than gadoxetate disodium, gadopentetate dimeglumine, or gadobenate dimeglumine. Gadolinium concentrations in the body are lowest after administration of gadoterate meglumine, gadobutrol, and gadoteridol. Instruct patients to inform their health care professional about all medical conditions, including if pregnant or thinking about becoming pregnant, dates and numbers of any previous gadolinium-enhanced MRIs, and history of kidney problems.
Administration of gadobutrol to patients with a history of gadolinium-based radiopaque contrast media hypersensitivity is contraindicated. The drug has been associated with serious, and sometimes fatal, anaphylactoid/anaphylactic reactions involving cardiovascular, respiratory, and/or cutaneous manifestations. In most cases, these reactions developed within 30 minutes of drug administration; however, delayed reactions may occur up to several days after administration. Prior to administration, assess hypersensitivity risk factors in all potential drug recipients. According to the American College of Radiology (ACR), the risk of adverse reactions is approximately 8-times higher in patients with a previous reaction to gadolinium-based contrast media; the subsequent reactions have the potential to be more severe than the first. Other individuals at increased risk include those with a history of asthma, atopy (including hay fever, food allergies, and drug allergies) or other allergic disorders. The manufacturer recommends appropriate facilities (trained personnel and therapies) be available for coping with the emergency treatment of severe reactions, and patients be closely observed for signs and symptoms of a hypersensitivity reaction during and after drug administration. One group of authors recommends taking similar precautions to those that are taken in patients who have previously reacted to iodinated radiopaque contrast media that require subsequent doses. First, the necessity of contrast enhancement during MRI should be determined. If it is determined that contrast enhancement outweighs any potential risk, the intensity of a previous reaction (to either iodinated or gadolinium-based contrast media) should guide precautionary measures. If the previous reaction to contrast media was mild or nonallergic, use of a different or low-osmolar (i.e., gadoteridol or gadodiamide) agent is recommended. If the previous reaction to contrast media was moderate or severe, premedication with steroids (e.g., prednisone or equivalent given 13, 7, and 1 hour prior to the exam; adult dose, 50 mg PO; pediatric dose, 0.5-0.7 mg/kg PO, up to 50 mg) and antihistamines (e.g., diphenhydramine given 1 hour prior to the exam; adult dose 50 mg IV/IM/PO; pediatric dose 1.25 mg/kg PO, up to 50 mg) along with the use of a different or low-osmolar contrast agent is recommended.
Serious adverse reactions, including nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy) (NSF/NFD), have been reported in patients with renal impairment after receiving gadolinium-based contrast agents (GBCAs), such as gadobutrol. NSF may result in fatal or debilitating systemic fibrosis affecting the internal organs, muscle, and skin. Patients at highest risk for NSF are those with chronic, severe renal disease or renal failure (glomerular filtration rate [GFR] less than 30 mL/min/1.73 m2) and patients with acute renal injury. Avoid use of GBCAs in patients with impaired drug elimination unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. Use of higher than recommended doses or repeated administration may increase the risk for NSF; therefore, administer the lowest dose necessary for adequate imaging and, if needed, only repeat the dose after a sufficient period of time has passed for elimination of the agent from the body. Gadobutrol is removed by hemodialysis. For patients receiving hemodialysis, it may be prudent to dialyze patients after receiving the contrast agents, although a relationship between dialysis and prevention of NSF has not been determined. Of note, hemodialysis is the preferred method of dialysis as continuous ambulatory peritoneal dialysis does not appear to be as effective in eliminating GBCAs. All patients should be screened for evidence of renal dysfunction by obtaining a medical history or laboratory results prior to the administration of GBCAs. Acute renal injury occurs commonly after surgery, severe infection, injury, or drug-induced renal toxicity. In patients with acute renal injury, serum creatinine concentrations and estimated GFR may not reliably assess renal function; therefore, obtaining a medical history in these patients is of utmost importance. For patients at risk of chronic renal disease (e.g., patients with hypertension, diabetes mellitus, or geriatric patients [older than 60 years of age]), estimate the GFR through laboratory testing. Counsel patients on the signs and symptoms of NSF/NFD. Report possible cases of NSF to the FDA through the FDA MedWatch program at 800-FDA-1088 and to the manufacturer at 888-842-2937. In contrast, guidelines suggest kidney function screening is optional for American College of Radiology (ACR) group II GBCAs, which includes gadobutrol, given risk of NSF is very low comparatively; the risk of NSF is very low for a standard dose (0.1 mmol/kg) of group II GBCA, even in patients with eGFR less than 30 mL/minute/1.73 m2. Do not withhold or delay group II GBCA in patients with kidney disease if harm would result from not proceeding with an indicated contrast-enhanced MRI. If multiple urgent group II GBCA doses are indicated, do not delay subsequent dose(s) for NSF concerns. If not urgent, delaying the subsequent dose(s) for more than 24 hours or performing intercurrent dialysis can promote GBCA clearance. In general, do not initiate or alter dialysis based on group II GBCA administration. These recommendations are not altered by patients receiving concomitant nephrotoxic medications, chemotherapy, or contrast-enhanced CT.
Ensure the patency and integrity of the intravenous line prior to administering gadobutrol. Further, appropriate surveillance of the dosing limb for development of local injection site reactions is recommended. Take care to avoid extravasation as tissue irritation (pain, burning, swelling, blistering, and necrosis) may occur. According to the American College of Radiology (ACR), the risk of significant injury from gadolinium-based contrast agents (GBCA) is extremely low, with GBCAs being much less toxic to the skin/subcutaneous tissue than equal volumes of iodinated contrast media.
Deoxygenated sickle erythrocytes have been shown in vitro to align perpendicular to a magnetic field which may result in vaso-occlusive complications in vivo. The enhancement of magnetic moment by gadolinium-based contrast agents (GBCAs), such as gadobutrol, may possibly potentiate sickle erythrocyte alignment. Although the use of gadobutrol in patients with sickle cell disease and other hemoglobinopathies has not been studied, the American College of Radiology (ACR) manual on contrast media considers any special risk to sickle cell patients from administration of GBCAs to be extremely low; no restrictions for use of GBCAs are recommended by the ACR.
Gadobutrol use in magnetic resonance angiography (MRA) has low sensitivity (55% or less) for detecting significant aortic stenosis, defined as more than 70% supra-aortic, or renal artery stenosis, defined as more than 50%. Therefore, a negative MRA study alone should not be used to rule out significant stenosis.
Gadobutrol is for intravenous use only. Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. Safety and effectiveness of gadobutrol have not been established with intrathecal use.
Use gadobutrol during pregnancy only if imaging is essential and cannot be delayed. Gadolinium-based contrast agents (GBCAs) cross the placenta and result in fetal exposure and gadolinium retention. Pregnant women may be at greater risk for gadolinium retention. Data on the association between GBCAs and adverse fetal outcomes in human pregnancy are limited and inconclusive. In animal studies, gadobutrol was not found to be teratogenic; however, at doses of 8- to 12-times the recommended human dose, gadobutrol was lethal to the embryo when administered to pregnant rats, rabbits, and monkeys. The American College of Radiology (ACR) manual on contrast media acknowledges that a standard gadolinium-based contrast agent (GBCA) crosses the primate placenta; however, the risk to the human fetus is unknown. Therefore, the ACR advises against GBCA routine use in pregnant women; GBCA should only be administered during pregnancy if absolutely necessary and only after informed consent is obtained. The Guidelines for Computed Tomography and Magnetic Resonance Imaging in Pregnancy and Lactation state that because of the potential for fetal toxicity, the drug should only be used during pregnancy if deemed absolutely essential.
There are no data on the presence of gadobutrol in human milk, the effects on the breast-fed infant, or the effects on milk production. Limited data demonstrates that breast-feeding after administration of another gadolinium-based contrast agent (GBCA) to the mother would result in the infant receiving an oral dose of 0.01% to 0.04% of the maternal dose. Gastrointestinal absorption of a GBCA is limited. Consider the developmental and health benefits of breast-feeding along with the mother's clinical need for gadobutrol and any potential adverse effects on the breast-fed infant from gadobutrol or the underlying maternal condition. Previous American Academy of Pediatrics (AAP) recommendations considered GBCAs compatible with breast-feeding. Additionally, the Guidelines for Computed Tomography and Magnetic Resonance Imaging Use During Pregnancy and Lactation and the American College of Radiology (ACR) manual on contrast media state that lactating women receiving GBCAs can continue to breast-feed without interruption. The reasoning for this recommendation is based on estimates of limited systemic exposure in the breast-fed infant and reviews that conclude maternally administered drug pose no risk to the nursing infant.
For use with magnetic resonance imaging (MRI) to assess myocardial perfusion in patients with known or suspected coronary artery disease, assess the presence and extent of malignant breast disease, and detect and visualize areas with disrupted blood-brain barrier and/or abnormal vascularity within the central nervous system (CNS):
-for cardiac MRI:
Intravenous dosage:
Adults: 0.05 mL/kg (0.05 mmol/kg) IV at peak pharmacologic stress, followed by 0.05 mL/kg (0.05 mmol/kg) IV at rest. The manufacturer provides weight-based dose volumes as follows (divided into 2 separate, equal injections): 35 kg: 3.5 mL; 40 kg: 4 mL; 45 kg: 4.5 mL; 50 kg: 5 mL; 60 kg: 6 mL; 70 kg: 7 mL; 80 kg: 8 mL; 90 kg: 9 mL; 100 kg: 10 mL; 110 kg: 11 mL; 120 kg: 12 mL; 130 kg: 13 mL; 140 kg: 14 mL.
-for MRI of the breast:
Intravenous dosage:
Adults: 0.1 mL/kg (0.1 mmol/kg) IV once. Imaging may begin after administration and then repeat sequentially to determine peak intensity and wash-out. The manufacturer provides weight-based dose volumes as follows: 35 kg: 3.5 mL; 40 kg: 4 mL; 45 kg: 4.5 mL; 50 kg: 5 mL; 60 kg: 6 mL; 70 kg: 7 mL; 80 kg: 8 mL; 90 kg: 9 mL; 100 kg: 10 mL; 110 kg: 11 mL; 120 kg: 12 mL; 130 kg: 13 mL; 140 kg: 14 mL.
-for MRI of the CNS:
Intravenous dosage:
Adults: 0.1 mL/kg (0.1 mmol/kg) IV once. Imaging may begin immediately after administration. The manufacturer provides weight-based dose volumes as follows: 35 kg: 3.5 mL; 40 kg: 4 mL; 45 kg: 4.5 mL; 50 kg: 5 mL; 60 kg: 6 mL; 70 kg: 7 mL; 80 kg: 8 mL; 90 kg: 9 mL; 100 kg: 10 mL; 110 kg: 11 mL; 120 kg: 12 mL; 130 kg: 13 mL; 140 kg: 14 mL.
Neonates, Infants, Children, and Adolescents: 0.1 mL/kg (0.1 mmol/kg) IV once. Imaging may begin immediately after administration. The manufacturer provides weight-based dose volumes as follows: 2.5 kg: 0.25 mL; 5 kg: 0.5 mL; 10 kg: 1 mL; 15 kg: 1.5 mL; 20 kg: 2 mL; 25 kg: 2.5 mL; 30 kg: 3 mL; 35 kg: 3.5 mL; 40 kg: 4 mL; 45 kg: 4.5 mL; 50 kg: 5 mL; 60 kg: 6 mL; 70 kg: 7 mL; 80 kg: 8 mL; 90 kg: 9 mL; 100 kg: 10 mL; 110 kg: 11 mL; 120 kg: 12 mL; 130 kg: 13 mL; 140 kg: 14 mL.
For use in magnetic resonance angiography (MRA) to evaluate known or suspected supra-aortic or renal artery disease:
Intravenous dosage:
Adults : 0.1 mL/kg (0.1 mmol/kg) administered as a single IV bolus injection by power injector at a rate of approximately 1.5 mL/second. Imaging should coincide with peak arterial concentration, which varies among patients. The manufacturer provides weight-based dose volumes as follow: 35 kg: 3.5 mL; 40 kg: 4 mL; 45 kg: 4.5 mL; 50 kg: 5 mL; 60 kg: 6 mL; 70 kg: 7 mL; 80 kg: 8 mL; 90 kg: 9 mL; 100 kg: 10 mL; 110 kg: 11 mL; 120 kg: 12 mL; 130 kg: 13 mL; 140 kg: 14 mL.
Neonates, Infants, Children, and Adolescents: 0.1 mL/kg (0.1 mmol/kg) administered as a single IV bolus injection by power injector or manually. Imaging should coincide with peak arterial concentration, which varies among patients. The manufacturer provides weight-based dose volumes as follow: 2.5 kg: 0.25 mL; 5 kg: 0.5 mL; 10 kg: 1 mL; 15 kg: 1.5 mL; 20 kg: 2 mL; 25 kg: 2.5 mL; 30 kg: 3 mL; 35 kg: 3.5 mL; 40 kg: 4 mL; 45 kg: 4.5 mL; 50 kg: 5 mL; 60 kg: 6 mL; 70 kg: 7 mL; 80 kg: 8 mL; 90 kg: 9 mL; 100 kg: 10 mL; 110 kg: 11 mL; 120 kg: 12 mL; 130 kg: 13 mL; 140 kg: 14 mL.
Maximum Dosage Limits:
-Adults
0.1 mL/kg (0.1 mmol/kg) IV single dose.
-Geriatric
0.1 mL/kg (0.1 mmol/kg) IV single dose.
-Adolescents
0.1 mL/kg (0.1 mmol/kg) IV single dose.
-Children
0.1 mL/kg (0.1 mmol/kg) IV single dose.
-Infants
0.1 mL/kg (0.1 mmol/kg) IV single dose.
-Neonates
0.1 mL/kg (0.1 mmol/kg) IV single dose.
Patients with Hepatic Impairment Dosing
Specific guidelines for dosage adjustments in hepatic impairment are not available; it appears that no dosage adjustments are needed.
Patients with Renal Impairment Dosing
No dosage adjustments are recommended. Do not exceed the recommended dose and allow sufficient time for elimination prior to any repeat administration. Avoid use in patients with chronic, severe renal disease (GFR < 30 mL/min/1.73m2) and in patients with acute kidney injury unless the diagnostic information is essential and not available with non-contrast imaging or other modalities; these patients are at highest risk for nephrogenic systemic fibrosis.
Intermittent hemodialysis
Gadobutrol is removed from the body by hemodialysis. For patients receiving hemodialysis, consider initiating a hemodialysis session after drug administration in order to enhance clearance of the contrast agent.
*non-FDA-approved indication
Bictegravir; Emtricitabine; Tenofovir Alafenamide: (Moderate) Monitor for changes in renal function if tenofovir alafenamide is administered in combination with nephrotoxic agents, such as radiopaque contrast agents. Tenofovir is primarily excreted via the kidneys by a combination of glomerular filtration and active tubular secretion. Coadministration of tenofovir alafenamide with a drug that reduces renal function or competes for active tubular secretion may increase concentrations of tenofovir and other renally eliminated drugs; thus, increasing the risk of developing renal-related adverse reactions.
Darunavir; Cobicistat; Emtricitabine; Tenofovir alafenamide: (Moderate) Monitor for changes in renal function if tenofovir alafenamide is administered in combination with nephrotoxic agents, such as radiopaque contrast agents. Tenofovir is primarily excreted via the kidneys by a combination of glomerular filtration and active tubular secretion. Coadministration of tenofovir alafenamide with a drug that reduces renal function or competes for active tubular secretion may increase concentrations of tenofovir and other renally eliminated drugs; thus, increasing the risk of developing renal-related adverse reactions.
Elvitegravir; Cobicistat; Emtricitabine; Tenofovir Alafenamide: (Moderate) Monitor for changes in renal function if tenofovir alafenamide is administered in combination with nephrotoxic agents, such as radiopaque contrast agents. Tenofovir is primarily excreted via the kidneys by a combination of glomerular filtration and active tubular secretion. Coadministration of tenofovir alafenamide with a drug that reduces renal function or competes for active tubular secretion may increase concentrations of tenofovir and other renally eliminated drugs; thus, increasing the risk of developing renal-related adverse reactions.
Emtricitabine; Rilpivirine; Tenofovir alafenamide: (Moderate) Monitor for changes in renal function if tenofovir alafenamide is administered in combination with nephrotoxic agents, such as radiopaque contrast agents. Tenofovir is primarily excreted via the kidneys by a combination of glomerular filtration and active tubular secretion. Coadministration of tenofovir alafenamide with a drug that reduces renal function or competes for active tubular secretion may increase concentrations of tenofovir and other renally eliminated drugs; thus, increasing the risk of developing renal-related adverse reactions.
Emtricitabine; Tenofovir alafenamide: (Moderate) Monitor for changes in renal function if tenofovir alafenamide is administered in combination with nephrotoxic agents, such as radiopaque contrast agents. Tenofovir is primarily excreted via the kidneys by a combination of glomerular filtration and active tubular secretion. Coadministration of tenofovir alafenamide with a drug that reduces renal function or competes for active tubular secretion may increase concentrations of tenofovir and other renally eliminated drugs; thus, increasing the risk of developing renal-related adverse reactions.
Tenofovir Alafenamide: (Moderate) Monitor for changes in renal function if tenofovir alafenamide is administered in combination with nephrotoxic agents, such as radiopaque contrast agents. Tenofovir is primarily excreted via the kidneys by a combination of glomerular filtration and active tubular secretion. Coadministration of tenofovir alafenamide with a drug that reduces renal function or competes for active tubular secretion may increase concentrations of tenofovir and other renally eliminated drugs; thus, increasing the risk of developing renal-related adverse reactions.
Tenofovir Alafenamide: (Moderate) Monitor for changes in renal function if tenofovir alafenamide is administered in combination with nephrotoxic agents, such as radiopaque contrast agents. Tenofovir is primarily excreted via the kidneys by a combination of glomerular filtration and active tubular secretion. Coadministration of tenofovir alafenamide with a drug that reduces renal function or competes for active tubular secretion may increase concentrations of tenofovir and other renally eliminated drugs; thus, increasing the risk of developing renal-related adverse reactions.
Gadobutrol, a paramagnetic agent, is used to enhance lesion detection and characterization during magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA). In magnetic resonance, the visualization of normal and pathological tissue depends on changes in the radiofrequency signal intensity that occur with: differences in proton density; differences of the spin-lattice or longitudinal relaxation time (T1); and differences in the spin-spin or transverse relaxation time (T2). Gadobutrol causes increased signal intensity by developing a magnetic moment when placed in a magnetic field. This magnetic moment causes the T1 and T2 relaxation times to shorten in target tissues. The extent by which gadobutrol decreases the T1 and T2 relaxation times, and subsequently enhances the signal, depends on the concentration of the drug within the tissue, field strength within the magnetic resonance system, and the relative ratio of T1 and T2. When administered at the manufacturer recommended dose, effects on T1 relaxation time are observed with the greatest sensitivity in T1-weighted magnetic resonance sequences.
Gadobutrol is administered intravenously. Following administration, the drug does not bind to any particular plasma protein; it rapidly distributes into the extracellular space. Gadobutrol does not undergo metabolism. It is excreted in the urine, via glomerular filtration, as an unchanged drug. The elimination half-life is approximately 2 hours, with > 90% of the administered dose eliminated within 12 hours.
Affected cytochrome P450 isoenzymes: none
-Special Populations
Renal Impairment
In patients with renal dysfunction, the systemic exposure (AUC) and serum half-life of gadobutrol are increased in correlation to the reduction in creatinine clearance. Following administration of a single dose to patients with mild to moderate renal impairment (CrCl > 30 to < 80 mL/min) and severe renal impairment (CrCl < 30 mL/min), the mean elimination half-life is 5.8 +/- 2.4 hours and 17.6 +/- 6.2 hours, respectively. Compared to patients with normal renal function, the mean AUC is increased from 1.1 +/- 0.1 mmol x h/L to 4 +/- 1.8 mmol x h/L and 11.5 +/- 4.3 mmol x h/L in patients with mild to moderate and severe renal impairment, respectively. A single hemodialysis session removes approximately 68% of the drug. The amount of drug removed is increased to 94% and 98% after a second and third dialysis session.
Pediatrics
Pharmacokinetic parameters (i.e., systemic drug exposure, plasma clearance, elimination half-life) of gadobutrol in pediatric patients are similar to those observed in adults. In patients aged 2-17 years, approximately 99% of an administered dose was recovered in the urine within 6 hours.
Geriatric
Compared with younger patients, administration of a single gadobutrol dose to a geriatric patient results in a systemic drug exposure (AUC) that is slightly higher and drug clearance that is slightly lower.